CLS has filed a new patent application for expanded and extended protection of the company's technology for laser-based tissue ablation until 2044.
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that a new patent application for expanded and extended protection for the company's technology has been filed.The current patent for CLS non-cooled laser applicators is valid until 2036 and has its origins in a collaboration that CLS initiated in 2010 with the German laser technology company Laser- und Medizin-Technologie GmbH, LMTB, regarding fiber development. In 2017, CLS purchased parts of LMTB and secured access to LMTB's patents and know-how for the unique diffuser technology. CLS diffuser-type laser